Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp Advanced Systemic Mastocytosis Topline Data Call Transcript

Sep 22, 2020 / 12:30PM GMT
Release Date Price: $87.27 (+13.03%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines Conference Call. (Operator Instructions)

I would now like to introduce your host for this conference call, Ms. Kristin Hodous of Blueprint Medicine. You may begin.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Thank you, operator. Good morning, everyone, and welcome to Blueprint Medicines Conference Call to discuss the top line data for our EXPLORER and PATHFINDER studies in advanced SM. You can access the press release announcing the data as well as the slides that we'll be reviewing today by going to the Investors and Media section of our website at www.blueprintmedicines.com. With me on the call today are: Jeff Albers, our Chief Executive Officer; Dr. Andy Boral, our Chief Medical Officer; and Christina Rossi, our Chief Commercial Officer.

Before we get started, I would like to remind everyone that statements we make on this conference call will include

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot